Brussels’s Pfizer’s immunization strategy | Sociedad

During this time it was rushed to Brussels, the European Commission announced that it had received 50 million additional doses of the Pfizer-BioNTech laboratory dose, which raised 250 million doses between April and June. , sufficient to immunize up to 125 million people, which is treated as a double pinchaza gun. The notice, announced by the President of the Executive Committee, Ursula von der Leyen, confirms the great European failure due to ARN messaging technology leaks, that the pandemic has never been used by humans, and specifically by the undeveloped injections that have been made months ago. , BioNtech, and elaborate with the support of the pharmaceutical giant Pfizer.

“We see that we are focused on the technologies that he demonstrated his efficiency. ARN’s vacancies are a clear example of this, ”assured the Commission’s Jefa, who also confirmed that the Commission negotiated with Pfizer-BioNTech a third contract with the end of receiving 1,800 million from its dose between 2021 and 2023 and with the vista being able to adapt to the new variants. Until the end, Brussels has agreed to buy up to 600 million doses of this company. “Ha demostrado ser un socio fiable”, ha dicho Von der Leyen. “Completes its compromises and responds to our needs”.

The European Union is committed to overcoming the hit of the 100 million inoculated doses to its citizens, of the 27 million cubits it has received the two requirements for the immunization, according to the proportions of the President of the Commission. Pfizer-BioNTech, which approved the first vacancy approved for use in the Community bloc and began administering it on 27 December, summed up around 63% of the total dose administered at the EU to close, according to the ECDC. Together with the Modern, the other vacant ARN caravan is approved and used between the Veintisiete, more than 70% of the entrants.

More information

Poco a poco, the pinchazos elaborados con esta nueva technology he ido ganande terreno y Bruselas center en ellas su strategy de immunización a corto, medio y largo plaza, mientras que parece ir arrinconando los pharmacos que usan virus at losostra, com de Jans cuales han ido accumulating countermeasures of distribution and security from the start of the campaign. Until recently, the Commission has authorized four vacancies to combat the pandemic: ARN messenger (Pfizer and Modern) and viral vector (AstraZeneca and Janssen).

Von der Leyen’s announcement is a one-off date that Janssen (a subsidiary of the Johnson & Johnson subsidiary) has decided to withdraw the first vouchers from its VE following the opinion of the United States authorities, which recommends suspending its use in the country to study six cases of thrombi detected between the millions of people to whom it has inoculated its pharmacy. The European Medicines Agency (EMA, by its seal in English) also informs the past four that it is investigating a possible angle between Janssen’s pinchas and the thromboembolic episodes, cases very similar to those with AstraZeneca.

A week ago, the regulator institution that had a causal relationship between the evacuation with the AstraZeneca pharmacy and the cases of Uruguayan blood coagulation detected in EU citizens who were administered this week, if any, EMA. The agency demands that the Anglo-Saxon laboratory warn of this “unusual” possibility in product information, although it recommends its use of the “effective lift” of the pharmacy to save lives.

Suministro problems

In addition to the security alerts, both AstraZeneca and Janssen have had problems compiling with the vial summit contracted with the EU. The first has protagonist of a constant referral to the Commission since March, when it was approved for its use in human beings, a tenure conflict including vocational nationalism in the pugna with the United Kingdom. AstraZeneca has acquired proportionally in the first quarter only 30 million of the 120 million dose doses initially, and Brussels is responsible for this laboratory, in large part, of the failure of all vacancy targets that the EU is marking 80 % of the population of more than 80 years and 80% of the sanitary staff).

Janssen, who received the red light from the EMA on March 11, has not yet been able to send the pact doses to the United States until he has received his approval. This week marks the start of the UE’s envoys, following the decision by the city authorities to suspend it. In the case of a vaccine mono dose, Janssen’s is one of the key injectors within the European strategy to target the target of immunizing up to 70% of vernacular adults. Brussels hopes to receive 55 million of this pharmacy in the second quarter, of which the correspondent in Spain is approximately 10%.

This Wednesday by the mañana, the diary La stampa Incidentally in the idea of ​​the Brussels apocalypse on the vehicles of ARN messenger. “The European Commission, in agreement with the leaflets of many countries, has decided that in the coming of the vigorous contracts for this year, those with companies that produce viral vector vacancies will not be renovated”, states the Italian periodical, citing a source of the Italian Ministry of Health.

From the Executive Communicator opinion, without embarrassment, that the information causes a mistake. “It is an English-language conclusion, certainly based on the inversion of ARN vehicles in the near future,” a European source said. In reality, the Executive does not renew contracts. Since the Commission launched in 2020 a first round of sales agreements anticipated by up to six different vacancy companies, Brussels has increased in February and February this year the contracts with Pfizer-BioNTech and Modern. The first of them, which has been compromised to deliver up to 600 million doses, has been converted into the large European vaccine, followed by Modern, which has already managed to deliver up to 460 million doses, 150 million of them in 2022.

The Commission decided to establish these new contracts, as explained at the moment, both by the technology used as well as by the production capacity of the laboratories and their potential to develop vacancies in front of the new variants of coronavirus.